We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

4 hedge funds and large institutions have $61.9M invested in Decoy Therapeutics in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

6% less capital invested

Capital invested by funds: $65.6M → $61.9M (-$3.74M)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
+$10.3M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$6.32M
2
Citigroup
Citigroup
New York
-$74K
3
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale
Germany
-$61K
4
BJ
BlackRock Japan
Japan
-$17K
5
AIS
Accurate Investment Solutions
Pennsylvania
-$4K

DCOY Hedge Fund Activity: Q2 2016 in Review

4 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q2 2016, worth a combined $61.9M — down 5.7% from $65.6M a quarter earlier.

Fund positioning in DCOY was balanced in Q2 2016: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was BlackRock Fund Advisors, opening a new position worth an estimated $10.3M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $6.32M sold.

  • 4 institutional investors held Decoy Therapeutics (DCOY) as of Q2 2016, unchanged from Q1 2016.
  • Funds reported $61.9M of Decoy Therapeutics stock for Q2 2016, down 5.7% quarter-over-quarter.
  • 1 fund opened new Decoy Therapeutics positions in Q2 2016 and 1 closed out, a net change of 0 holders.
  • The largest Decoy Therapeutics buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $10.3M added.
  • The largest Decoy Therapeutics seller in Q2 2016 was EcoR1 Capital, an estimated $6.32M sold.

Based on aggregated 13F filings for Q2 2016.